{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:46:47Z","timestamp":1793652407330,"version":"4.5.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.diabet.2018.02.001","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T07:37:11Z","timestamp":1518507431000},"page":"410-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"44","author":[{"given":"D.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Yufeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2018.02.001_bib0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jama.293.2.217","article-title":"Preventing foot ulcers in patients with diabetes","volume":"293","author":"Singh","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2018.02.001_bib0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2337\/diacare.13.5.513","article-title":"Pathways to diabetic limb amputation. Basis for prevention","volume":"13","author":"Pecoraro","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.02.001_bib0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3111\/13696998.2014.882843","article-title":"Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012)","volume":"17","author":"Ward","year":"2014","journal-title":"J Med Econ"},{"key":"10.1016\/j.diabet.2018.02.001_bib0020","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1016\/j.jvs.2015.10.005","article-title":"A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome","volume":"63","author":"Hasan","year":"2016","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.diabet.2018.02.001_bib0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2018.02.001_bib0030","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.02.001_bib0035","unstructured":"FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). US Food and Drug Administration. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm557507.htm. Accessed May 16, 2017."},{"key":"10.1016\/j.diabet.2018.02.001_bib0040","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the EASEL Population-Based Cohort Study","author":"Udell","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.02.001_bib0045","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2018.02.001_bib0050","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 510","article-title":"Chapter 8: assessing risk of bias in included studies","author":"Higgins","year":"2011"},{"key":"10.1016\/j.diabet.2018.02.001_bib0055","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.diabet.2018.02.001_bib0060","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.02.001_bib0065","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2337\/dc14-2365","article-title":"Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes","volume":"38","author":"Lewin","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.02.001_bib0070","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc14-2364","article-title":"Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","volume":"38","author":"DeFronzo","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.02.001_bib0075","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Haring","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.02.001_bib0080","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"Haring","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.02.001_bib0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2018.02.001_bib0090","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1262-3636(07)70238-0","article-title":"Factors associated with diabetic patients at high risk for foot ulceration","volume":"31","author":"Leymarie","year":"2005","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2018.02.001_bib0095","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2337\/diacare.18.4.509","article-title":"Risk factors for lower extremity amputation in persons with diabetes","volume":"18","author":"Selby","year":"1995","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.02.001_bib0100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jvs.2010.06.100","article-title":"The Semmes Weinstein monofilament examination is a significant predictor of the risk of foot ulceration and amputation in patients with diabetes mellitus","volume":"53","author":"Feng","year":"2011","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.diabet.2018.02.001_bib0105","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","article-title":"SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System","volume":"5","author":"Fadini","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2018.02.001_bib0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2018.02.001_bib0115","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2018.02.001_bib0120","unstructured":"EMA Pharmacovigilance Risk Assessment Committee recommendation: PRAC concludes that diabetes medicine canagliflozin may contribute to risk of toe amputation. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SGLT2_inhibitors_Canagliflozin_20\/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee\/WC500221431.pdf. Accessed February 10, 2017."},{"key":"10.1016\/j.diabet.2018.02.001_bib0125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00592-016-0928-z","article-title":"Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials","volume":"54","author":"Monami","year":"2017","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabet.2018.02.001_bib0130","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2018.02.001_bib0135","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with Type 2 diabetes: a 24-week, multicenter, randomized, double-blind, Placebo-Controlled Study with a 28-week extension","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.02.001_bib0140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/dc13-2762","article-title":"Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study","volume":"38","author":"Leiter","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.02.001_bib0145","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstrale","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2018.02.001_bib0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","article-title":"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2018.02.001_bib0155","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.02.001_bib0160","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2018.02.001_bib0165","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with Type 2 Diabetes: pooled analysis of Phase I-III Clinical Trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv Ther"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363618300417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363618300417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T22:21:14Z","timestamp":1539296474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363618300417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1262363618300417"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2018.02.001","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2018.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}